retatrutide triple agonist gip glp-1 glucagon receptor Retatrutide—A Game Changer in Obesity Pharmacotherapy The power of three: Retatrutide's

Background Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM)

Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021

*Benefits as shown are reported in ingredient-specific studies

Genetics integration available: Add the Precision Peptide Genetic Test post-purchase ($99 one-time) for genetic insights across 14 health pathways

GLP-1 is a hormone that the gut produces after eating to regulate blood sugar, slow digestion and manage hunger

#Vitalnutrients #GLP1Complete #Innovation #MetabolicHealth #AppetiteControl